AbbVie is a global, research-based biopharmaceutical company committed to developing innovative advanced therapies to address some of the world's most complex and critical conditions. AbbVie's mission is to use its expertise, dedicated people, and unique approach to innovation to markedly improve treatments across key therapeutic areas including immunology, oncology, neuroscience, and eye care, along with products and services across its Allergan Aesthetics portfolio. The company strives to have a remarkable impact on people’s lives.
Serves as the central hub for global operations, corporate strategy, research and development leadership, and key administrative functions.
The campus, known as AbbVie Park, hosts state-of-the-art research laboratories, modern office buildings, and various employee amenities designed to foster collaboration and scientific innovation. It includes advanced facilities for drug discovery and development.
AbbVie's headquarters fosters a culture centered on scientific rigor, innovation, collaboration, and patient-centricity. Employees are encouraged to pursue groundbreaking research and contribute to a diverse and inclusive workplace.
The headquarters is strategically positioned within a significant life sciences corridor, facilitating access to talent and research partnerships. It represents the core of AbbVie's global efforts to discover and deliver transformative medicines.
AbbVie has a significant global presence, operating in more than 70 countries. Its worldwide functions include extensive research and development facilities, a global network of manufacturing and supply chain operations, comprehensive commercial activities (including marketing, sales, and market access), clinical trial management across numerous regions, and localized corporate support functions. This widespread infrastructure allows AbbVie to discover, develop, manufacture, and deliver its innovative medicines to patients around the globe.
1 North Waukegan Road
North Chicago
Illinois
USA
Address: Knollstrasse 50, 67061 Ludwigshafen am Rhein, Germany
Serves as a critical hub for AbbVie's operations in Europe, supporting clinical development, product manufacturing and supply, and fostering R&D collaborations within the European market and globally.
Address: 100 Research Drive, Worcester, MA 01605, USA
Leverages the rich talent pool and biotech ecosystem of the Greater Boston area to drive innovation in AbbVie's biologics pipeline, contributing to global drug development efforts.
Address: 2525 Dupont Dr, Irvine, CA 92612, USA
Serves as a major center for AbbVie's aesthetics business and plays a key role in the company's presence on the U.S. West Coast, an important hub for medical and biotech innovation.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AbbVie' leadership includes:
AbbVie has been backed by several prominent investors over the years, including:
AbbVie has seen key leadership transitions in the past year, including a retirement and subsequent promotion in its commercial leadership, and a significant new appointment in its R&D organization, reflecting strategic focus on its pipeline and commercial execution.
Discover the tools AbbVie uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AbbVie most commonly uses the email format 'first.last@abbvie.com'. This is the standard convention for employee email addresses at the company. While minor variations might exist for specific cases, this format has a high success rate for reaching AbbVie employees.
first.last@abbvie.com
Format
john.smith@abbvie.com
Example
90%
Success rate
AbbVie News Center • May 21, 2024
AbbVie announced the U.S. FDA granted accelerated approval for EPKINLY® (epcoritamab-bysp) to treat adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. EPKINLY is the first T-cell engaging bispecific antibody approved for this indication....more
AbbVie News Center • April 26, 2024
AbbVie announced its financial results for the first quarter ended March 31, 2024. The company reported net revenues of $12.310 billion, with strong growth from Skyrizi and Rinvoq, and highlighted progress in its pipeline. Adjusted diluted EPS was $2.31....more
Endpoints News • May 14, 2024
Following its $8.7 billion acquisition of Cerevel Therapeutics, AbbVie is optimistic about emraclidine, a neuropsychiatric drug candidate for schizophrenia and Alzheimer's disease psychosis, projecting it as a potential multi-billion dollar future blockbuster....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AbbVie, are just a search away.